News_BriSTAR

03.23 2023
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

01.31 2023
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference January 31, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Marquis during February 6-9, 2023.

01.19 2023
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS January 19, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.

09.19 2023
BriSTAR Immunotech Announces the Addition of Dr. Christopher J. Paige as a Member of the Company's Scientific Advisory Board On September 19, 2022 - TORONTO & BEIJING -- BriSTAR Immunotech announced that Dr. Christopher J. Paige, a world-renowned leader in the field of lymphocyte development and antibody formation and an expert in immunotherapy, has joined the company's Scientific Advisory Board.

01.15 2022
BriSTAR Immunotech Limited wins the KPMG China "First Top 50 Biotechnology Innovation Enterprises" Award 2022 On June 15, 2022, KPMG China releases the list of "the First Top 50 Biotechnology Innovation Enterprises 2022". With its excellent innovation strength and development potential, BriSTAR Immunotech Limited is successfully included into the list through screening and evaluation by KPMG China and industry experts after about 10 months.

10.11 2021
BriSTAR Immunotech Limited completed the round B financing of more than 200 million Yuan: Accelerating the Development of Innovative Cell Therapy Drugs for Meeting the Clinical Needs of the Patients with Advanced Cancer On October 11, 2021, BriSTAR Immunotech Limited announces that it has completed round B financing of more than RMB 200million in Beijing, China. This round of financing was led by the China Growth Capital.

06.17 2021
EHA 2021丨 BriSTAR Immunotech Limited releases the latest data on CD19/CD20 Dual STAR-T Therapy R/R B-ALL The articles come from eMedClub. The "Innovative CD 19/CD 20 Dual STAR-T Cell Therapy for the Treatment of Refractory/ Relapse (R/R) Acute B-Lymphocyte Leukemia (R/R B-ALL)" jointly launched by BrisSTAR Immunotech Limited with Ludaopei Hospital is honored to be one of the few studies selected in the special report of the EHA conference.

02.08 2021
Cover Story of ASH 2020 | BriSTAR Immunotech Limited's innovative STAR-T is reported at the headlines of the Hematology News, the official journal of the American Society of Hematology The phase I clinical study of T cell therapy, an innovative STAR technology platform jointly developed by BriSTAR Immunotech Limited and Tsinghua University, is first appeared on the international stage and becomes one of the few studies selected as the oral report at the meeting of ASH 2020.

12.07 2020
Oral Report at ASH 2020 | research data on innovative STAR-T product for the treatment of R/R B-ALL The research paper entitled “a Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)” independently developed by China Immunotech (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as "BriSTAR Immunotech Limited") is selected as the oral report at the meeting of ASH 2020 after strict review, making a voice on the international stage.

03.09 2020
BriSTAR Immunotech Limited successfully completes the round a financing of 45million Yuan In January 2020, BriSTAR Immunotech Limited successfully completes round A of financing of 45 million Yuan. This round of financing is led by the Shanghai Jianxin Equity, with joint investments by the Guanghua Venture Capital and the Zhejiang Huacheng Group. Previously, BriSTAR Immunotech Limited also received tens of millions of Yuan of early investment by the Lotus Lake Capital and the QF Capital.